Abstract
SERPINA3K, a member of the serine proteinase inhibitor (SERPIN) family, shows significant therapeutic potential for treating corneal neovascularization (NV) and inflammation. In a rat alkali burn model, topical application of SERPINA3K (20 µg/eye/day) significantly reduced the area of NV and improved the inflammatory index compared to controls. Mechanistically, SERPINA3K rebalances the corneal environment by down-regulating pro-angiogenic (VEGF) and pro-inflammatory (TNF-α) factors while up-regulating anti-angiogenic (PEDF) and regenerative (EGFR) factors. These findings highlight SERPINA3K as a promising multi-target therapeutic for corneal injury.
Introduction
Corneal injuries, particularly chemical alkali burns, are a leading cause of visual impairment worldwide. Such injuries trigger a destructive cascade characterized by intense inflammation and corneal neovascularization (NV)—the abnormal growth of blood vessels into the clear cornea. This combination often leads to permanent scarring and blindness. Current treatments are frequently insufficient or associated with significant side effects. There is a critical need for "multi-target" molecules that can simultaneously suppress pathological vessel growth and inflammation while promoting epithelial healing. This study investigates SERPINA3K, a protein known for its protective effects in the retina, as a potential therapeutic agent for the cornea.
Methods
The study employed a rat alkali burn model and in vitro cell culture experiments. Male Wistar rats received a controlled alkali burn (1N NaOH) and were treated topically with SERPINA3K (20 µg/eye/day), BSA, or PBS for 7 days. Clinical outcomes were evaluated using slit-lamp microscopy to measure NV area and an inflammatory index to quantify redness and swelling. Fluorescein staining tracked corneal epithelial healing. Molecular changes were assessed via Western blotting and immunofluorescence for VEGF, TNF-α, PEDF, and EGFR. Additionally, the effects of SERPINA3K on Human Umbilical Vein Endothelial Cells (HUVEC) and Human Corneal Epithelial (HCE) cells were tested using MTT assays to measure cell viability and growth.
Results and Key Insights
Reduced Neovascularization and Inflammation
By day 8, SERPINA3K-treated eyes showed a significantly smaller area of blood vessel growth compared to PBS or BSA controls ($p < 0.001$). The inflammatory index was also significantly reduced by day 5 and remained lower through day 8. Histological analysis confirmed reduced corneal thickening and fewer infiltrating inflammatory cells in the SERPINA3K group.
Enhanced Epithelial Healing
Fluorescein sodium staining revealed that the epithelial defect was smaller and the corneal surface was smoother in SERPINA3K-treated eyes. This indicates that the treatment not only prevents damage but actively accelerates the repair of the eye's outermost layer.
Molecular Rebalancing: The VEGF:PEDF Seesaw
Corneal health depends on a delicate balance between pro-angiogenic (VEGF) and anti-angiogenic (PEDF) factors. SERPINA3K treatment shifted this balance by significantly decreasing levels of the pro-angiogenic factor VEGF and the pro-inflammatory cytokine TNF-α, while simultaneously increasing levels of the anti-angiogenic factor PEDF.
Cell-Specific Action and EGFR Up-regulation
In vitro tests showed that SERPINA3K inhibited the growth of vascular endothelial cells (HUVECs) but had no negative impact on corneal epithelial cells (HCEs). Crucially, the study identified a novel role for SERPINA3K in up-regulating EGFR expression in the corneal epithelium, providing a mechanistic basis for its pro-healing effects on the ocular surface.
Discussion and Future Directions
SERPINA3K acts as a potent dual-action agent, suppressing the "blindness-inducing" duo of inflammation and NV while actively promoting surface repair. Its ability to up-regulate EGFR represents a significant finding in corneal wound healing research. However, the exact signaling pathways through which SERPINA3K triggers this increase remain to be fully elucidated; authors suggest a potential link to the Wnt pathway.
While the rat model effectively mimics human pathology, translational research is needed to account for differences in human corneal thickness and healing kinetics. Future studies should also evaluate the long-term effects of SERPINA3K on preventing chronic fibrosis (scarring) and maintaining long-term corneal clarity.
Summary updated